# Biosynthesis of PGD2 in Vivo

> **NCT01275300** · NA · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 9 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Aspirin
- **DRUG:** Placebo
- **DRUG:** Niacin

## Key facts

- **NCT ID:** NCT01275300
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275300, "Biosynthesis of PGD2 in Vivo". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT01275300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*